Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Glucocorticoid Receptor Agonist Market: Competitive Landscape, Pipeline, and Market Analysis 2024
Glucocorticoid Receptor Agonist Market: Competitive Landscape, Pipeline, and Market Analysis 2024
The glucocorticoid receptor (GR, or GCR), also known as NR3C1 (nuclear receptor subfamily 3, group C, member 1), is the receptor to which cortisol and other glucocorticoids bind. The GR is expressed in almost every cell in the body and regulates genes controlling the development, metabolism, and immune response. GCR Agonist drugs act by binding the glucocorticoid agonist, which induces a conformational change in the glucocorticoid receptor, leading to its activation. This activated receptor-ligand complex is then translocated into the nucleus. In the nucleus, the activated glucocorticoid receptor binds to specific DNA sequences known as glucocorticoid response elements (GREs) located in the regulatory regions of target genes, and once bound to the GREs, the activated glucocorticoid receptor complex interacts with other proteins and transcriptional co-regulators resulting in the recruitment of transcriptional machinery and the modulation of gene expression which will lead to the upregulation or downregulation of specific target genes.
GCR Agonist treats asthma, respiratory tract diseases, lung diseases, digestive system diseases, dermatitis, rhinitis, autoimmune disorders, and skin diseases. Increased prevalence of respiratory tract infections and allergic rhinitis are the key drivers for the GCR agonist market. For instance, according to the Centers for Disease Control and Prevention 2021, around there were 4.6% of adults who have ever been diagnosed with COPD, emphysema, or chronic bronchitisThe introduction of newer products by market players may look for opportunities that greatly impact comprehensive research and development in GCR Agonist inhibitors. For instance, AstraZeneca launched Breztri Aerosphere to treat COPD. For instance, GSK’s GSK870086 Inhalation for the indication of Asthma is under the various stages of clinical studies.
Key Market Developments:
Approved Drug Molecules and Brand Names for GCR Agonist:
Drugs under the Pipeline for GCR Agonist:
Clinical Activity and Developments of GCR Agonist:
Up until July 2023, there will be about more than 70 companies with over 100 compounds that focus on various forms of respiratory diseases, and skin diseases. For these molecules, more than 1600 of clinical trials are being conducted and majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,
|
Molecule Name |
Number of Studies |
|
GSK870086 Inhalation |
12 |
|
AZD5423 |
7 |
|
Tri-Luma (Fluocinolone /Hydroquinone/Tretinoin) |
6 |
|
Budesonide (MAP0010) |
6 |
|
Dexamethasone Sustained-Release (TLC599) |
5 |
The molecules such as Breztri Aerosphere (Budesonide/Glycopyrrolate/Formoterol Fumarate) developed by AstraZeneca are specifically indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease. Breztri Aerosphere is formulated as an aerosol for oral inhalation. Moreover, Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/Vilanterol) developed by GlaxoSmithKline is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease and the maintenance treatment of asthma in patients aged 18 years and older. Trelegy Ellipta is formulated as a powder for oral inhalation.
Total sales of GSK's Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/Vilanterol) for the second quarter ended at US$254 million in FY2020 globally, which is a 58% increase from the same period in FY2019. Trelegy's new leg up in asthma will lead it in its fight against rival British drugmaker AstraZeneca's Breztri Aerosphere, which is also pursuing a nod in asthma after its initial FDA approval earlier in 2020. After receiving a thorough response letter from the FDA, the medicine Breztri took more than a year to receive approval. In the pivotal phase 3 study for that regulatory file, the inhaler failed to meet one of its nine key objectives. Still, AstraZeneca eventually submitted data from another phase 3 study that helped the medication through the finish line. Moreover, the increased aging population and incidence of hypersensitivity disorders and allergic rhinitis create an opportunity for the future and burgeon the growth of the GCR agonist market. For instance, according to the Centers for Disease Control and Prevention 2021, around 8% of the US adult population suffers from asthma and related complications, which are expected to create a lucrative opportunity for the GCR Agonist market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Breztri Aerosphere (Budesonide/Glycopyrrolate/Formoterol Fumarate), Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/Vilanterol) are few FDA-approved GCR Agonist.
Total sales of GSK’s Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/Vilanterol) for the second quarter ended were US$254 million in FY2020 globally.
AstraZeneca, GSK, Clearside Biomedical, Bausch Health, etc are few leading market players in GCR Agonist market.
Asthma, respiratory tract diseases, lung diseases, digestive system diseases, dermatitis, rhinitis, autoimmune disorder, and skin diseases, etc are the major indication of GCR Agonist.
There are more than 60 molecules that are in Phase-1, Phase-2, and Phase-3 clinical development.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.